Bio­gen fi­nal­ly scores win in its fight to pre­vent copy­cats of MS drug in the EU

Af­ter fail­ing to block gener­ics for Tec­fidera in the US, Bio­gen snagged a win in Eu­rope in its fight to pre­vent copy­cat ver­sions of its block­buster mul­ti­ple scle­ro­sis drug.

Ac­cord­ing to SEC fil­ings, the Eu­ro­pean Com­mis­sion (EC) on Wednes­day let Bio­gen know that it de­cid­ed to ex­tend reg­u­la­to­ry mar­ket pro­tec­tion of Tec­fidera (di­methyl fu­marate) un­til Feb. 2, 2025. Bio­gen will have ex­clu­sive rights in Eu­rope with­out the threat of oth­er com­pa­nies de­vel­op­ing gener­ics with the same ac­tive in­gre­di­ents.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA